SCHEDULE: Bank of America Discloses 6.7% Stake in Fulcrum Therapeutics

Bank of America Corp /DE/ has reported beneficial ownership of 4,468,123 shares, representing 6.7% of the common stock of Fulcrum Therapeutics, Inc.

Summary

• Bank of America Corp /DE/ has filed a Schedule 13G, indicating a change in its beneficial ownership of Fulcrum Therapeutics, Inc. common stock.
• The filing reports that Bank of America Corp /DE/ beneficially owns 4,468,123 shares of Fulcrum Therapeutics' common stock.
• This ownership stake represents 6.7% of the total outstanding shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
• The beneficial ownership calculation is based on 66,633,321 outstanding shares as disclosed by Fulcrum Therapeutics in its Form 10-Q on April 27, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without indicating new investment strategy or significant company performance.

Positives

• Bank of America Corp /DE/ has a significant beneficial ownership stake (6.7%) in Fulcrum Therapeutics, Inc., which could indicate confidence or a strategic position.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a standard investment practice rather than a hostile takeover attempt.

Negatives

• The filing does not provide any information regarding the financial performance or strategic direction of Fulcrum Therapeutics, Inc.
• The nature of Bank of America's investment (e.g., for trading, lending collateral, or long-term investment) is not detailed.

Risks

• The filing does not explicitly mention any risks associated with Fulcrum Therapeutics, Inc. or Bank of America's investment.
• Potential risks for shareholders could include market volatility affecting the value of Fulcrum Therapeutics' stock, which is not addressed in this filing.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Fulcrum Therapeutics, Inc.'s future performance.

Management Comments

• "The beneficial ownership calculation relies on the 66,633,321 outstanding shares disclosed in the Form 10-Q by the issuer on April 27, 2026, which reports share totals as of April 20, 2026."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like Bank of America when their beneficial ownership of a public company's stock crosses a certain threshold. This filing indicates a passive investment position rather than an active attempt to influence the company's operations.

Stakeholder Impact

• Shareholders of Fulcrum Therapeutics, Inc. may see the filing as a sign of institutional interest, though the passive nature of the ownership limits immediate impact on control.
• Creditors and suppliers of Fulcrum Therapeutics, Inc. are unlikely to be directly impacted by this ownership disclosure.

Next Steps

• Bank of America Corp /DE/ will continue to hold its shares in Fulcrum Therapeutics, Inc. in the ordinary course of business.
• Fulcrum Therapeutics, Inc. will continue its operations as disclosed in its other SEC filings.

Key Dates

Keywords

Fulcrum Therapeutics, Bank of America, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Securities